CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- B-Cell Acute Lymphoblastic Leukaemia
- B Cell Lymphoma
- B Cell Malignancy
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
This is a single-center, Open Label phase I clinical trial, 9 subjects planned to be enrolled. The subjects will be divided into low-dose group, medium-dose group and high-dose group.Dose CAR+ cells/kg Low 1×105 Medium 2×106 High 6×106
This is a single-center, Open Label phase I clinical trial, 9 subjects planned to be enrolled. The subjects will be divided into low-dose group, medium-dose group and high-dose group.Dose CAR+ cells/kg Low 1×105 Medium 2×106 High 6×106
Tracking Information
- NCT #
- NCT03559439
- Collaborators
- Gracell Biotechnology Ltd.
- Investigators
- Principal Investigator: Ligen Liu Shanghai Tong Ren Hospital
Get Well Soon